A Note From Dean Charney

The Icahn School of Medicine at Mount Sinai is a bold leader in scientific exploration, biomedical education, and clinical care. As we drive science forward, our eyes are always on the goal of translating our findings into new diagnostics and therapies that can improve human health. Our purpose is to expand medicine’s capacity to save more lives and to improve the quality of life for patients.
Our students are among the best and brightest in the nation. They receive an outstanding education here at Icahn Mount Sinai. To ensure that education remains among the best in the country we are innovating—Icahn Mount Sinai is about to introduce our new ASCEND curriculum. It emphasizes early and continuous development of clinical reasoning skills throughout our students’ education.
Many of our scientists have heard me say, “Don’t fear failure.” And they don’t. They are intrepid explorers, willing to take chances, because that is how we are able to meaningfully advance science and medicine and deliver discoveries that matter, discoveries that can improve the lives of our patients. Thanks to your success, our funding is growing rapidly, and we are expanding our research and clinical facilities.

At the Icahn School of Medicine at Mount Sinai, we see where science is heading. We understand the potential of new technology that can help us change the world. So, we have invested in the tools and the people who can take us into the future. We have built powerful capabilities in Artificial Intelligence, or, as I like to call it, “Augmented Intelligence”. Now we’re reaping the benefits of our strategy—and this is only the beginning of our payoff.
A Note From Dean Charney

We recruit the best and the brightest—and our brilliant scientists and clinicians are delivering stellar results. They are taking on the biggest challenges, the toughest diseases, like complex cancers and degenerative brain disease—and they’re making impressive progress.
Only a select few academic medical centers can do what we’re doing: significantly advance science; apply research breakthroughs to develop new diagnostics and treatments; deliver the very best clinical care; and educate the next generation of great physicians, researchers, and health care leaders. Mount Sinai is doing all of this! So, as I speak with you today, I can report that the state of the Icahn School of Medicine at Mount Sinai is outstanding!

Let’s review the details.
Research That Makes a Difference in the Lives of Patients

**Heart**

**FEBRUARY 23, 2023**

Fasting negatively affects immune cells and could lead to increased risk of heart disease

Henrike Janssen; Florian Kahles; Dan Liu; Jeffrey Downey; Laura L. Kowklee; Vladmir Roudoi; Danvor D’Souza; Cameron S. MacKinnon;Leonard Halle; Wolfram C. Poller; Christopher T. Chan; Shun He; Jie E. Mindur; Malik G. Kiss; Sumima Singh; Atsushi Arai; Yushitoku Isaworo; Rainer H. Kohler; Kaushal Chhabl; Ruslan I. Sadreyev; Rajesh Weisleder; Sengheo Kim-Schulze; Miriam Merad; Matthias Nahrendorf; Filip, K. Serak

**JULY 6, 2023**

Study establishing potential of novel gene delivery vector to treat heart failure

Xiuhong Li; Sabrina La Salvia; Yaxuan Liang; Marta Adamia; Erik Kohlbrenner; Dongtak Jeong; Elana Chepurko; Deliana Ceholski; Estrella Lopez-Gordo; Seonghun Yoon; Prabhu Methyaugan; Neha Agarwal; Divya Jha; Shweta Lodha; George Daaboul; Anh Pham; Nilshi Rasinghara; Shihong Zhang; Xia Zhao; Edgar Gonzalez-Kozlov; Nicola Dubois; Namedi Doga; Roger J. Hajjar; Susmita Sareo

**OCTOBER 12, 2023**

First “multiome” atlas of brain cell development in the human cerebral cortex

Kaiq Zhu; Jaroslaw Benda; Samir Rahman; James M. Voci; Claire Coleman; Teresa Clare; Oriban Labache; Nadeija M. Tsarkova; Alcinu Li; Kristen J. Bremerand; Donghoon Lee; Guo-cheng Yuan; John F. Fullard; Pavlos Roussos

**Cancer**

**JULY 27, 2023**

RNA therapy combats melanoma (collaboration with Institute for Genomic Technology)

Yuebao Zhang; Xucheng Hou; Shi Du; Yonger Xue; Jingyue Yan; Diana D. Kang; Yichen Zhong; Chang Wang; Binbin Deng; David W. McComb; Yizhou Dong

**SEPTEMBER 20, 2023**

Biomarker that tracks recovery from treatment-resistant depression identified

Sankaraaarengam Alagapan; Ki Suing Choi; Stephen Heiskig; Patricio Riva-Possa; Andrea Cresci; Vinay Tiruvadi; Mosadoluwa Obasuan; Ashan Veenakumar; Allison C. Waters; Robert E. Gorsa; Simon Quinn; Lydia Dorst; Matthew O’Shaughnessy; Marissa Connor; Gregory Canat; Jungho Cha; Rachel Hershberger; Tanya Nauval; Faisal Ilati; Muhammad Furqan Afzal; Martin Fogel; Brian R. Kopeit; Robert Bukata; Helen S. Mayberg; Christopher J. Rozell

**Genetics and Genomic Sciences**

**MARCH 13, 2022**

Novel genes linked to schizophrenia are identified

Dongling Liu; Dana Meyer; Brian Fennessy; Claudia Feng; Esther Cheng; Jessica S. Johnson; You Jeong Park; Marysia-Kolbe Riecker; Steven Ascoliott; Agathe de Pires; Amanda Dobbion; Daniselle Lebouzh; Emily Moya; Tan-Hoang Nguyen; Lilian Wittke; Amane Hassain; Psychiatric Genomics Consortium Phase 3 Targeted Sequencing of Schizophrenia Study Team; Katherine E. Burdick; Joseph D. Oskiub; Emilio Domenici; Sophia Francon; Annemate M. Martin (); Claudina Laurent-Levinnson; Drena Mockta; Carolina R. Pat; Michèle T. Plate; Keny Rossier; Pancs Roussos; Dan Ruevais...
Recognized for Research Excellence

 Ranked No. 14 in total NIH funding among all U.S. medical schools

 Source: NIH, 2023

 16 basic and clinical science departments in top 20 NIH funding

 Source: Blue Ridge, 2023

 99th percentile among U.S. private medical schools in indirect research dollars per investigator

 Source: AAMC, 2023
Our NIH Funding Is Growing: 2014–2023 ($ in Millions)
### Department Rankings for NIH Funding: Top 20

#### Basic Sciences

<table>
<thead>
<tr>
<th>Rank</th>
<th>Department</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Neuroscience</td>
<td>$32.6M</td>
</tr>
<tr>
<td>2</td>
<td>Genetics</td>
<td>$44.7M</td>
</tr>
<tr>
<td>3</td>
<td>Pharmacology</td>
<td>$21.8M</td>
</tr>
<tr>
<td>9</td>
<td>Microbiology</td>
<td>$19.8M</td>
</tr>
<tr>
<td>13</td>
<td>Cell Biology</td>
<td>$13.8M</td>
</tr>
</tbody>
</table>

#### Clinical Sciences

<table>
<thead>
<tr>
<th>Rank</th>
<th>Department</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Emergency Medicine</td>
<td>$13.3M</td>
</tr>
<tr>
<td>4</td>
<td>Public Health</td>
<td>$32.8M</td>
</tr>
<tr>
<td>6</td>
<td>Physical Medicine</td>
<td>$2.59M</td>
</tr>
<tr>
<td>6</td>
<td>Psychiatry</td>
<td>$49.9M</td>
</tr>
<tr>
<td>7</td>
<td>Urology</td>
<td>$3.44M</td>
</tr>
<tr>
<td>11</td>
<td>Internal Medicine</td>
<td>$147M</td>
</tr>
<tr>
<td>15</td>
<td>Orthopedics</td>
<td>$2.96M</td>
</tr>
<tr>
<td>17</td>
<td>Neurosurgery</td>
<td>$3.66M</td>
</tr>
<tr>
<td>17</td>
<td>Family Medicine</td>
<td>$1.74M</td>
</tr>
<tr>
<td>20</td>
<td>Pediatrics</td>
<td>$22.3M</td>
</tr>
<tr>
<td>20</td>
<td>Radiology</td>
<td>$12.6M</td>
</tr>
</tbody>
</table>

Source: Blue Ridge 2023 Data
Icahn Mount Sinai Is a Research Powerhouse

**Mount Sinai Million Health Discovery Program**
- Expanded to children and collaborations with minority institutions
- Alexander W. Charney, MD, PhD; Girish N. Nadkarni, MD, MPH

**Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern**
- $16 million from NIH
- Adolfo García-Sastre, PhD; Benhur Lee, MD; Matthew Evans, PhD; Lisa Miorin, PhD; Christopher Basler, PhD; Gustavo Palacios, PhD

**Allen Discovery Center for Neuroimmune Interactions**
- $10 million from Allen Institute
- Brian Kim, MD, PhD; Miriam Merad, MD, PhD; others

**Innovation in Cancer Diagnostics and Treatment**
- $16 million from NIH, Multiple Myeloma Foundation, others
- Samir Parekh, MBBS; Brown Brian, PhD; Miriam Merad, MD, PhD; Keith Sigel, MD, PhD; others
What’s on the Horizon: Research

• **AI/Machine Learning:** Placing all of Mount Sinai’s clinical data into the Mount Sinai Data Ark, which will include EHR information, brain/body scans and images, digital pathology, and genomic information, allowing unprecedented ability to mine data for clinical insights

• **Clinical Trials:** Aiming to triple the number of clinical trials

• **Center for Human Disease Modeling** to drive cell systems, study disease pathophysiology, and develop novel treatments

• **Novel Therapeutics** that can turn on the immune system against tumors
  - Immune cell therapy for cancer
  - Innovative treatments for a wide range of disorders

• **Pioneering the next generation of RNA and DNA therapies**
  - New nanoparticle formulations to deliver RNAs and CRISPRs to specific organs to treat disease
  - CRISPR-based therapies for mono-genic disorders such as cystic fibrosis and sickle cell anemia
  - Using RNA analogs and drug cocktails to create a cancer vaccine from a patient’s tumors

Eric Nestler, MD, PhD
Dean for Academic Affairs
Chief Scientific Officer
Research Spaces

787 11th Avenue
- Clinical, ASC, and Research Wet Labs
- Misc. Departments

619 West 54th Street
- Center for Engineering and Precision Medicine

3 East 101st Street
April completion
- Admin, Dry Lab / Computational Space
- Rehab, Emergency Department, Biomedical Engineering and Imaging Institute, Artificial Intelligence, and Genetics
# Accelerating Innovation and Entrepreneurship: Mount Sinai Innovation Partners

<table>
<thead>
<tr>
<th><strong>904</strong></th>
<th><strong>59</strong></th>
<th><strong>305</strong></th>
<th><strong>140</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty Engagements</td>
<td>Licenses and Options</td>
<td>Research Contracts</td>
<td>Technology Disclosures</td>
</tr>
<tr>
<td><strong>268</strong></td>
<td><strong>1,110</strong></td>
<td><strong>311</strong></td>
<td></td>
</tr>
<tr>
<td>New Patent Applications</td>
<td>Material Transfer Agreements</td>
<td>Confidentiality Disclosures</td>
<td></td>
</tr>
</tbody>
</table>

(Provides $34.7M in funding)
## Mount Sinai Innovation Partners Spinoffs

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>CastleVax</td>
<td>Cell BioEngines is a clinical-stage biotech company focused on developing 'off-the-shelf' allogeneic cell therapies as 'drugs' to turn all cancers into curable diseases.</td>
</tr>
<tr>
<td>Cell BioEngines</td>
<td>Cell BioEngines licensed and is advancing Mount Sinai technologies for the purpose of developing a dendritic cell-based immunotherapy for the treatment of head and neck cancers and a cord blood stem cell treatment for hematologic malignancies.</td>
</tr>
<tr>
<td>LinusBio</td>
<td>Named one of Fierce Biotech's 2024 Fierce 15, LinusBio is developing novel biomarker-based diagnostics and prognostics for the early diagnosis of autism spectrum disorder and ADHD.</td>
</tr>
<tr>
<td>PreciseDX</td>
<td>PreciseDx received New York State Department of Health approval for its advanced AI-enabled breast cancer diagnostic. The company's AI algorithms stratify cancer risk to support precision treatment and care strategies for breast and other cancers.</td>
</tr>
</tbody>
</table>
Mount Sinai Innovation Partners Spinoffs, Cont’d

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>GNOMX</td>
<td>Diagnostic tests for infections, specific pathogens, and antibiotic sensitivity.</td>
</tr>
<tr>
<td>Paratus Sciences</td>
<td>Paratus Sciences is committed to improving human health and health security. By advancing the development of licensed Mount Sinai technologies in the field of bat biology, the company aims to develop new therapies in the fields of infectious disease, oncology, metabolism, and aging.</td>
</tr>
<tr>
<td>Renalytix</td>
<td>KDIGO guidelines, FDA, and pending CMS Local Coverage Decision</td>
</tr>
<tr>
<td>Trellus Health</td>
<td>The company’s principal product, Trellus Elevate, is a multidisciplinary virtual care support system that surrounds IBD and GI patients with the team and tools to help them manage Crohn’s disease, ulcerative colitis, and irritable bowel syndrome. Trellus Health initiated pilot testing of Trellus Elevate with a major health plan in March 2024.</td>
</tr>
</tbody>
</table>
New Treatment — Rejoyn

Dr. Dennis Charney in partnership with Dr. Brian Iacoviello has spearheaded the development of the first prescription digital treatment for major depressive disorder. This innovative treatment, Rejoyn™, has just received approval from the U.S. Food and Drug Administration (FDA). Rejoyn™ incorporates scientifically validated cognitive emotional brain training exercises, such as the Emotional Faces Memory Task, to tackle the complexities of major depressive disorder.
Accelerating Translational Research Through New Research and Educational Initiatives

Institute and Center Directors

- Michal Elovitz, MD, Institute for Women’s Biomedical Research
- Sarah Millar, PhD, Institute for Regenerative Medicine
- David Muller, MD, Institute for Equity and Justice in Health Sciences Education
- Scott Friedman, MD, Institute for Liver Research
- Louis Pasquale, MD, Institute for Eye and Vision Research
- Alex Manini, MD, MS, Center for Research on Emerging Substances, Poisoning, Overdoses, and New Discoveries (RESPOND)
- Panos Roussos, MD, PhD, Center For Disease Neurogenomics
- James Tsai, MD, Center for Ophthalmic Artificial Intelligence and Human Health
New Appointments and Promotions

Chairs

Neil M. Rofsky, MD, MHA
Department of Diagnostic, Molecular and Interventional Radiology

Ana Fernandez-Sesma, PhD
Department of Microbiology

Miriam Merad, MD, PhD
Department of Immunology and Immunotherapy

David C. Thomas, MD, MPHE
Department of Medical Education

Rosalind Wright, MD, MPH
Department of Public Health

Chiefs

Sean Pinney, MD
Cardiology Chief, Mount Sinai Morningside

Michael F. Murray, MD
Chief of the Division of Genomic Medicine

Meena Bansal, MD
Chief of the Division of Liver Diseases

Admin

Lorisa Richards, DNP, MS, RN, FNP, NEA-BC
Acting Chief Nursing Officer, The Mount Sinai Hospital

Jenny Waltzer
Vice President, Oncology and Therapeutic Infusion Services
New Appointments and Promotions

Deans

Yvette Calderon, MD, MS  
Equity and Clinical Care

Paul Lawrence, MFA  
Scholarly and Research Technologies

Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN  
Mount Sinai Phillips School of Nursing

David C. Thomas, MD, MPHE  
Medical Education

Rosalind Wright, MD, MPH  
Public Health

Miriam Merad, MD, PhD  
Translation Research and Therapeutic Innovation

Sarah Millar, PhD  
Basic Science

Senior Associate Deans

Alexis Colvin, MD  
Alumni Affairs

Rachel Posner  
Research Administration

Carol Gregorio, PhD  
Basic Science

Associate Deans

Jack Suben  
Design and Resource Management

Lori Jennex  
Program for the Protection of Human Subjects
Department of Public Health

- Establish PhD in Public Health
- Expanding Public Health Masters programs
- Adding courses in climate and health, global health equity, AI and public health, geoinformatics
- Integrating public health across Icahn Mount Sinai research

Rosalind J. Wright, MD, MPH
Dean of Public Health Chair, Department of Public Health
Department of Immunology and Immunotherapy

Miriam Merad, MD, PhD
Chair, Department of Immunology and Immunotherapy
Dean, Translation Research and Therapeutic Innovation
Director, Precision Immunology Institute

- Pursuing a comprehensive understanding of the immune system and its impact on human health and disease
- Developing advanced gene and cell engineering technologies to study the immune system
- Exploring how cancer contributes to dysregulation of the immune system
- **Discovery**: Allergy drug can improve lung cancer outcomes
Opportunities for Career Growth: Investigator Track Faculty

Icahn Mount Sinai’s robust faculty development and mentoring programs make us an attractive institution for early-stage and mid-career faculty.

32 New Investigator Track Faculty in:

- AI and Human Health
- Cell Developmental and Regenerative Biology
- Dermatology
- Diagnostic, Molecular, and Interventional Radiology
- Emergency Medicine
- Environmental Medicine and Public Health
- Genetics and Genomic Sciences
- Global Health and Health System Designs
- Immunology and Immunotherapy
- Medicine
- Microbiology
- Neurology
- Neuroscience
- Obstetrics, Gynecology and Reproductive Science
- Oncological Sciences
- Ophthalmology
- Orthopedics
- Otolaryngology
- Pathology, Molecular and Cell-Based Medicine
- Pediatrics
- Pharmacological Sciences
- Psychiatry
- Rehabilitation and Human Performance
Advancing Women in Leadership Roles at Icahn Mount Sinai: Office of Gender Equity in Science and Medicine

Carol R. Horowitz, MD, MPH
Dean

Toni A. Stern, MD, MBA
Senior Associate Dean

Jenny Lin, MD
Senior Associate Dean

• Cultivating leaders
  – Five new Distinguished Scholars for Junior faculty who are caregivers
  – Two new programs for women faculty: Mid-career and Senior Leadership

• Advancing equity amongst caregivers
  Gender Equity Action Teams:
  – Promoting Mount Sinai’s family-friendly policies
  – Normalizing those who use their caregiving benefits
  – Tracking gender representation

• Eliminate gender bias in communications
  – Project on “Enhancing Mutual Respect”

• NASEM Action Collaborative

Amplifying Equity: A Series for Advancing Gender Equity in Science & Medicine
Center for Stress, Resilience, and Personal Growth (CSRPG)

Deborah B. Marin, MD
Director, Center for Stress, Resilience, and Personal Growth

Jonathan M. DePierro, PhD
Clinical Director, Center for Stress, Resilience, and Personal Growth

- Delivered more than 8,000 confidential behavioral health care visits for employees and their adult co-insured dependents
- 268 workshops and huddles focused on mental health and resilience, including in the EDs, ICUs, and more than 20 GME programs (HRSA-funded)
- Resilience-building Wellness Hub mobile app available to all MSHS faculty and staff
- Work featured in Resilience: The Science of Mastering Life’s Greatest Challenges (Third ed.) and multiple peer-reviewed articles
MENTAL HEALTH AWARENESS

**REDuce Grant**
- Distributed more than $400,000 in pilot grant support to mitigate clerical and administrative burden

**Response to Faculty Survey**
- Mental health resource expansion, leadership/mentorship training, Epic enhancements

**Well-Being Champions**
- 40+ Faculty Champions, 50+ GME Champions
- 17 departmental plans to address well-being

**Residents and Fellows**
- Grants to support innovations reducing GME clerical burden/clinical intensity
- Increased mental health and peer support

**Medical and Graduate Students, Postdocs**
- PEERS program: “Practice, Enhancement, Engagement, Resilience Support”
- Expanded wellness advisors, developed community events, enhanced mental health and crisis support services
Medical Education

David C. Thomas, MD, MS, MHPE
Dean and Chair, Medical Education

ASCEND Curriculum: Fall, 2024
• 18 months: pre-clerkship.12 months: clerkship.18 months: post-clerkship
• First in nation: Palliative Medicine clerkship, Chronic Care clerkship
• Dedicated faculty mentor
• Emphasizes student wellness, resiliency, and progressive career and professional development

New Fellowships for MD students
• Leadership in Health care Equity and Administration Scholar Program
• Surgeon Scientist Training Program
Medical Education: Attracting a Diverse Group of the Best and the Brightest Students

<table>
<thead>
<tr>
<th>Number of Matriculating Students</th>
<th>MD/MD–PhD Matriculated 2023</th>
<th>FlexMed Accepted 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-Identifying as Woman</td>
<td>64 (53%)</td>
<td>22 (54%)</td>
</tr>
<tr>
<td>Underrepresented in Medicine/Science</td>
<td>34 (28%)</td>
<td>19 (46%)</td>
</tr>
<tr>
<td>Number of Undergraduate Schools</td>
<td>55</td>
<td>23</td>
</tr>
<tr>
<td>Median MCAT</td>
<td>517</td>
<td>N/A</td>
</tr>
<tr>
<td>Median GPA</td>
<td>3.92</td>
<td>3.97</td>
</tr>
</tbody>
</table>

Excellence in Student Research

- 73 Students graduated with distinction in research
- 147 Students presented at national or international conferences
- 20 students published in high-impact journals

Class of 2024 Match and Graduation

- 133 students matched into 26 specialties
- 50 students entered residency within the Mount Sinai Health System
Graduate School of Biomedical Sciences: Attracting a Diverse Group of the Best and the Brightest Students

2023 PhD Students in Biomedical Sciences and Neuroscience

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Size of Class</td>
<td>57</td>
</tr>
<tr>
<td>Women</td>
<td>71%</td>
</tr>
<tr>
<td>Underrepresented in Science</td>
<td>19%</td>
</tr>
<tr>
<td>Median Undergraduate GPA</td>
<td>3.68</td>
</tr>
</tbody>
</table>

Strengths of the Incoming Class of PhD Students

• Students are from 14 different countries
• 37 percent of students have undergraduate degrees in quantitative sciences
• About 200 publications across all students

Recruitment of the largest class for the MSBS program in our history, with 53 new matriculants (20 percent increase over the past five years)
Graduate School of Biomedical Sciences

• Fully integrating AI, Data Science, Computational Biology across curricula
• Partnering with National Science Foundation Innovation Corps
• Offering more than 100 hours training in Biomedical Entrepreneurship
• Expanding Public Health Master’s program

Marta Filizola, PhD
Dean, Graduate School of Biomedical Sciences

• First accredited fellowship program in Health Care Management and Leadership in the United States
• Planning PhD program in Health Sciences Engineering
• Enhancing mentorship
A Leader in Graduate Medical Education
Our graduate medical education program remains the largest in the United States

<table>
<thead>
<tr>
<th>Program name</th>
<th>No. of Programs in the U.S.</th>
<th>2023 Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occupational Health</td>
<td>23</td>
<td>3</td>
</tr>
<tr>
<td>Phys Med/Rehab</td>
<td>107</td>
<td>8</td>
</tr>
<tr>
<td>Dermatology</td>
<td>147</td>
<td>10</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>300</td>
<td>12</td>
</tr>
<tr>
<td>Radiology Diagnostic</td>
<td>200</td>
<td>13</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>130</td>
<td>15</td>
</tr>
<tr>
<td>Radiology Nuclear Medicine</td>
<td>37</td>
<td>15</td>
</tr>
<tr>
<td>Neurology</td>
<td>178</td>
<td>16</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>622</td>
<td>18</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>287</td>
<td>19</td>
</tr>
<tr>
<td>Anesthesiology</td>
<td>165</td>
<td>19</td>
</tr>
<tr>
<td>Obstetrics-Gynecology</td>
<td>301</td>
<td>21</td>
</tr>
<tr>
<td>Pathology</td>
<td>147</td>
<td>27</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>90</td>
<td>27</td>
</tr>
<tr>
<td>Internal Medicine/Pediatrics</td>
<td>79</td>
<td>28</td>
</tr>
</tbody>
</table>

2,650 residents and clinical fellows in 250 GME programs

I. Michael Leitman, MD
Surgery
Pursuing Reaccreditation From Middle States Commission on Higher Education

- 2.5 year process culminating with submission of a “Self-Study” report, followed by site visit in Spring, 2025.

- Self-Study process: introspective examination of how our educational programming is linked to our institutional mission and strategic goals.

- Steering Committee oversees five Working Groups conducting the Self-Study and will prepare the final report for Middle States.

- Steering Committee and Working Groups are comprised of faculty, administrators, staff, and students with a broad set of backgrounds and expertise.
Gary Butts, PhD
Chief Diversity and Inclusion Officer
Dean for Diversity Programs, Policy, and Community Affairs

Road Map for Action to Address Racism

- Promoting equitable culture
- Training to engage in anti-racism and equitable practices
- Strategic partnerships, policy changes
- Retention and development of under-represented minorities
- Stand against all forms of hate speech

- Anti-Racist Transformation (ART) in Med Ed
- Modeling our Road Map: Journal of Academic Medicine
- DEI Summit
- Conference: Transforming Landscape of Medical Education
Making Icahn Mount Sinai a More Equitable and Anti-Racist Institution: Road Map for Action

We Stand in Solidarity Against Racism.
And We Are Committed to Equity in Health Care.
Institute for Equity and Justice in Health Sciences Education

David Muller, MD
Director, Institute for Equity and Justice in Health Sciences Education

Leona Hess, PhD, MSW
Co-Director, Institute for Equity and Justice in Health Sciences Education

• Teach health sciences educators to dismantle and disrupt all forms of racism and bias, including Islamophobia and Anti-Semitism
• Oversee the change management strategy to accelerate anti-racist and anti-bias transformation in health sciences education at Icahn Mount Sinai
• Serve as a national resource for best practices and consultation
Institute for Health Equity Research: Reducing Health Disparities and Supporting Health Equity

• Influenced U.S. Organ Procurement and Transplantation Network to reform race-based approach that disadvantaged black patients awaiting a transplant

• Developed a community-based intervention to prevent suicide among black youth

• Pioneering AI approaches to uncover and address stigmatizing language in EHRs

• Addressing disparities in mortality for non-English speaking hospital patients

• Supporting deployment of “equity dashboards” to improve quality of clinical care

Carol R. Horowitz, MD, MPH
Director

Lynne D. Richardson, MD
Co-Director
Mount Sinai Doctors Faculty Practice: Highlights

Ambulatory Volume

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of Arrived Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>4,873,940</td>
</tr>
<tr>
<td>2023</td>
<td>5,255,302</td>
</tr>
</tbody>
</table>

8% Increase

Patient Receipt Growth

MSDFP Total Patient Receipts (2019–2023)

<table>
<thead>
<tr>
<th>Years</th>
<th>Billions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>$1,086,444</td>
</tr>
<tr>
<td>2021</td>
<td>$1,155,474</td>
</tr>
<tr>
<td>2022</td>
<td>$1,234,713</td>
</tr>
<tr>
<td>2023</td>
<td>$1,343,789</td>
</tr>
</tbody>
</table>

24% Increase
Mount Sinai Doctors Faculty Practice: Highlights

**MyMountSinai**
- 1.7M active users (16% increase year over year)
- 25K activations per month

**Digital Bookings**
- 22% of all appointments are booked digitally, up from 5% in 2019

**Central Billing Office**
- Charges $4.9B (up 10%)
- Cash Collections $1.2B (up 13%)
What’s on the Horizon: Ambulatory Practice

Expand **MSHS presence** through **organic growth, partnerships, and acquisition** to further **advance** our **tertiary and quaternary** care within the Mount Sinai Health System

**Drive the clinical enterprise** to further support the **educational and research** mission of the Mount Sinai Health System

**Access and Ambulatory Growth**

- **Increase market share** through continued innovation and unparalleled **access**
  - New patient acquisition
  - Improved continuity of care and domestic utilization for existing patients
  - Optimize existing external relationships
  - Establish new external partnerships

- **Purpose-build a patient-centered consumer experience** leveraging **technology, access, and ease of use**

---

**Kelly Cassano, DO**
Chief Executive Officer, Mount Sinai Doctors Faculty Practice
Dean for Clinical Affairs
Senior Vice President for Ambulatory Operations, Mount Sinai Health System
Expanding Our Presence in Neighborhoods Where Our Patients Live and Work

158 West 124th Street
373 Park Avenue South
787 11th Avenue
Showcasing Ichan Mount Sinai’s Reputation for Research and Academic Excellence

- Two new *Science* Supplements in 2023
- Print and digital copies sent to all subscribers
- Podcast segments

- Five *Health Affairs* editorials throughout 2023
- 580,000 monthly readers
- Website banner ads

- “A.I. in Human Healthcare” two-day symposium
Institutional Advancement: MSHS “Limitless” Capital Campaign Public Phase

First Comprehensive Capital Campaign for Health System: $2.0B (2017–2025)

- Raised to Date (as close of 2023): $2.05B (100% of goal)
- Raised in 2023: $477.3M

- 2017–2020 Nucleus Phase
- 2021–2025 Public Phase

$633.6M Strategic Programs
$1.268B Other Strategic Areas
$253.2M Strategic Capital
Many of these accomplishments would not have been possible without the support of an exceptional human being—Dr. Ken Davis. More than two decades ago, Dr. Davis gave up his research career to become Chief Executive of what was then Mount Sinai Medical Center. He led Mount Sinai out of a financial crisis and made possible the tremendous growth we have experienced. He has been my partner through my many years as Dean of the School of Medicine. Thank you, Ken, for all you’ve done for Icahn Mount Sinai and the entire Mount Sinai Health System.
Under the leadership of our new Chief Executive Officer, Dr. Brendan Carr, Mount Sinai will achieve new heights of excellence across our three-part mission. Dr. Carr is a renowned expert in emergency medicine and health care policy. He led our emergency department through its epic battle against the COVID-19 pandemic and has also served as a visionary leader in Washington, advocating for essential improvements in the public-private partnership for emergency preparedness.
Mission Statement

The Icahn School of Medicine at Mount Sinai advances science, medicine, and health care delivery for the benefit of humanity through a culture of excellence, innovation, collaboration, and inclusive diversity. We conduct groundbreaking research; educate and nurture the next generation of exceptional clinicians, researchers, teachers, and leaders; and deliver the most advanced compassionate care with an unwavering commitment to health equity.

“It is never wrong to do the right thing.”

MARK TWAIN
I also want to thank all of you for your hard work. Because of you, Icahn Mount Sinai is a bold and innovative school of medicine.

It is thanks to your outstanding clinical care that saves and improves the lives of our patients; your breakthrough research that is unlocking the mysteries of disease and accelerating our progress towards new diagnostics and therapies; your love of teaching; and your dedication to educate the next generation of scientists, physicians, and health professionals. For all these reasons, Icahn Mount Sinai stands among the great medical schools of the world.

I am deeply appreciative of all you do for Icahn Mount Sinai—and for the collaboration and support you give each other, all in the interest of advancing science and medicine for the benefit of humanity.

Thank you!
Thank you

April 2024